New insider activity at Artivion ( (AORT) ) has taken place on August 28, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marshall S. Stanton, the Senior Vice President of Clinical & MD Affairs at Artivion, has recently sold 18,200 shares of the company’s stock. This transaction amounted to a total value of $801,164.
Recent Updates on AORT stock
Artivion has experienced significant developments recently, with several analysts raising their price targets for the company. The positive adjustments are largely attributed to Artivion’s strong Q2 earnings report, which showcased impressive revenue and EBITDA growth, successful product launches, and improved financial stability. The company’s constant currency revenue growth improved significantly, driven by strong performance in the On-X and stent graft segments. Additionally, Artivion’s innovation pipeline, including NEXUS and Arcevo, has shown promising progress. Despite some challenges, such as costs from a cybersecurity incident and delays in the China BioGlue launch, the overall outlook remains optimistic, with raised guidance reflecting confidence in the company’s growth strategy.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
Artivion’s overall score is driven by strong earnings call results and positive corporate events, but is weighed down by financial performance challenges and lack of technical analysis data.
To see Spark’s full report on AORT stock, click here.
More about Artivion
YTD Price Performance: 55.77%
Average Trading Volume: 419,993
Technical Sentiment Signal: Buy
Current Market Cap: $2.08B